stervc
7 hours ago
BDPT 8-K New Auditor...
BDPT 8-K New Auditor...
https://www.otcmarkets.com/filing/html?id=17535806&guid=RrQ-k619PyECJth
On May 11, 2024, BioAdaptives’ Board approved the appointment of Boladale Lawal & Co as the Company’s new independent registered PCAOB firm, effective immediately to perform independent audit services for the fiscal year ending December 31,2024 and also the reviews of its quarterly reporting of 2024. Furthermore, Boladale Lawal & Co. will audit the balance sheet of the Company as of December 31, 2023, and the related statements of operations, stockholders’ equity and cash flows for the year then ended. Based upon the audits, Boladale Lawal & Co. will issue a written report on the Company’s financial statements as well.
v/r
Sterling
KeepItRealistic
5 days ago
$BDPT used 1800 Diagonal Lending, LLC extensively…
U.S. SECURITIES AND EXCHANGE COMMISSION
Litigation Release No. 25995 / May 7, 2024
Securities and Exchange Commission v. Power Up Lending Ltd., et al., No. 1:24-cv-03498 (S.D.N.Y. filed May 7, 2024)
SEC Sues Curt Kramer and Three of His Businesses for Acting as Unregistered Securities Dealers
The Securities and Exchange Commission announced today charges against Curt Kramer of Jericho, New York, and his wholly owned businesses Power Up Lending Ltd., Geneva Roth Remark Holdings, Inc., and 1800 Diagonal Lending, LLC (formerly known as Sixth Street Lending LLC), for operating as unregistered securities dealers.
The SEC's complaint, filed in the United States District Court, Southern District of New York, alleges that since at least January 2018 through at least March 2023, Kramer and his companies engaged in the business of purchasing convertible securities from penny stock issuers, converting those securities into common stock at a large discount from the prevailing market price, and quickly selling the newly issued shares into the market for a profit. The SEC's complaint alleges that the Defendants purchased nearly 2,000 convertible securities from about 325 microcap stock issuers, converted the securities into more than 100 billion newly-issued shares of common stock, rapidly sold the newly issued shares into the market, and generated millions of dollars in revenues and profits. As alleged, Kramer and his companies were not registered as dealers with the SEC or associated with a registered broker-dealer, as their activities required them to do.
The SEC's complaint charges Kramer, Power Up, Geneva Roth, and 1800 Diagonal with violating the dealer registration provision of Section 15(a)(1) of the Securities Exchange Act of 1934 ("Exchange Act"), and also alleges Kramer is liable as a control person of his companies pursuant to Section 20(a) of the Exchange Act. The SEC seeks a permanent injunction, disgorgement of ill-gotten gains plus prejudgment interest, civil penalties, a penny stock bar, and other equitable relief.
The SEC's investigation was conducted by Stephen LeBlanc and supervised by Lisa Deitch and Stacy Bogert. The litigation will be led by Suzanne Romajas, Daniel Lloyd, and Stephen LeBlanc, and supervised by Christopher Bruckmann.
Ribo
4 weeks ago
🚨 $BDPT
💰0.0006
Pink Current, AS: 1.2B, OS: 1.2B, US: 1.2B
Update Delay: 72 hours
Held at DTC Shares Updated:
🔴 1,193,342,585 (2024-04-05)
🟢 1,213,356,474 (2024-04-12)
Difference: +1.7% (+20M)
Outstanding Shares Updated:
🔴 1,
https://t.co/MRUvBTUUO2— OTC Updates (@OtcUpdates) April 15, 2024
AverageJoe
1 month ago
$BDPT about to fly in my opinion!: 12. SUBSEQUENT EVENTS
On October 11 2023, the Company filed a new Reg A for the marketing of 250,000,000 common shares at a price range of $0.001 to $0.003, to be determined after qualifying. This new Reg A is to provide additional funding for the marketing for BioAdaptives itself, and also for its wholly owned subsidiary, LiveStock Impact Inc, The Company is looking to expand its range of targeted human health supplements. It is also focused on the marketing effort of LiveStock Impact, Inc and its wholesale activities as well as its interest in botanical drugs. Towards this end, since October, the Company has been working with a professional entity on its press releases and marketing promotions. It expects to intensify its marketing outreach in the next two quarters. In January 2024, the Company launches an innovative food Lab for the development of treats and supplement powder for human, equine and canine. The initial trials were conducted in an established kitchen facility. In January 2024, BioAdaptives signed a Distributor’s agreement with PIXELCANDO SL to distribute FitYourOutfit® (FYO) product in North America. This is a low-cost AI smart phone app body composition tracking system to detect unwanted muscle mass loss reported with obesity management and also fat loss. In conjunction with its BodyShape Lab division and the AI FYO system product, the Company acquired the distribution rights of an All-In-One dietary supplement formula,, NaturaComplete™.This new formula provides a comprehensive array of over 70 vitamins, mineral, amino and fatty acids, trace minerals and other nutrients to support general health and obesity management activities. It is expected that NaturaComplete™ will be marketed within the first 2 quarters of 2024 together with Pluripain PMS™, which is designed to help manage the symptoms associated with the menstrual cycle and VeganHepplus™, a liver support supplement. Two equine products: Equine All-In-On Extreme and Equine All-In-One Extreme Booster will both be actively launched in the first two quarters of 2024 for competition and performance horses.
LJ-Bodhi
1 month ago
The OS is not maxed out. Read page 41 of the annual report:
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The following table sets forth certain information as of December 31, 2023, regarding the number of shares of Common Stock beneficially owned by (i) each person or entity known to us to own more than five percent of our Common Stock; (ii) each of our Named Executive Officers; (iii) each of our directors; and (iv) all of our executive officers and directors as a group. The percentages are based on 895,750,225 total outstanding Shares as of December 31, 2023.
1.25 billion AS
895 million OS
200 million shelf registration still being actively marketed to sell new shares.
One lender who has converted around 600m shares and dumped on the market. Still converting and dumping. Chart of all conversions is on pages 15 and 16. Dilution is ongoing and AS will likely be raised again soon.
https://www.otcmarkets.com/filing/html?id=17441285&guid=O_Q-kF378EKfJth#BDPT_10K_HTM_I12
powerbattles
1 month ago
Look at my past posts to find my opinion—all the details are there. As of now, the fundamentals have shifted. When I initially discovered the stock, the outstanding shares were less than 300 million, and it had a strong run at that time. "On September 8, 2023, the Company registered its Livestock Impact Division as a wholly owned subsidiary in Nevada with 200,000,000 shares authorized and 10,000,000 preferred shares. The Livestock Impact Division is supposed to spin-off, in a spin-off, the parent company declares a special dividend payable in shares of the subsidiary company, but they can't execute the plan. If they can't follow through with the spin-off, and market the products which was the primary reason I invested in the stock, then I can't do much about it. I informed everyone that I was giving them until December to finalize the spin-off, and if they couldn't, I would have to move on. I sold my last share in Feb.
At this point the o/s near max out which is for the trip 0 I think is still very low. For the short term, people can easily flip 30% to 100% profit if they buy at this current price .0004 to .0006. In the long term. The company needs working capital at this time the only way to fund the company is to dilute the shares. On October 11, 2023, the Company filed a Form 1-A with the Securities Exchange Commission covering a plan to sell up to 250,000,000 shares of common stock for prices between $0.001-0.003. This filing is ongoing as indicated it will be challenging to move the share above the .001 mark.
Yet, there remains hope for them if they can successfully raise additional funds without diluting the shares and effectively market their products to consumers. GLTA!
Effective April 2023, FCBR Therapy Division has been appointed its exclusive Distributor for all LiveStock Impact’s products; the Company also negotiated with the supplier for the exclusive marketing rights to these products from the non-exclusive license it has held since June 2022. In this first quarter of the exclusive wholesale agreement, its wholesale volume has surpassed the past 9 months total by 400%. Granted due to the switch from retail to wholesale the margins are much tighter, but we believe in 2024, the expanded sales will greatly benefit this wholly owned subsidiary and will justify its eventual independence.
The Company is also negotiating distribution rights to three additional human products: Pluripain PMS™, which is designed to help manage the symptoms associated with the menstrual cycle; VeganHepplus™, a liver support supplement; as well as NaturaComplete™, an All-In-One dietary supplement formula with over 70 vitamins, mineral, amino and fatty acids, trace minerals and other nutrients to support general health and obesity management activities. These three new products are expected to be in market within first six months of 2024.
LJ-Bodhi
1 month ago
According to the annual report, sadly dilution is not finished, it is ongoing and they disclosed their intend to dilute more in the future as their only means of funding operations.
There is a chart showing how many hundreds of thousands of shares their lender has already converted, along with the dates. Since they cannot own more than 4.99% at a time, we now know 100% that lender is the entity repeatedly converting, dumping on the market, reloading, rinse and repeat.
Additionally the company disclosed it is still actively marketing shares under the current shelf registration and may need to reduce the offer price further to generate interest. They are currently priced way above the OTC market price.
All can be verified in the 10K they just filed:
https://www.otcmarkets.com/filing/html?id=17441285&guid=6zQ-kWTpsQmSJth